Free Trial
→ Your blueprint for crypto wealth (From Crypto 101 Media) (Ad) Free KALV Stock Alerts

KalVista Pharmaceuticals (KALV) Financials

KalVista Pharmaceuticals logo
$12.41 -0.25 (-1.97%)
Closing price 08/8/2025 04:00 PM Eastern
Extended Trading
$12.68 +0.27 (+2.14%)
As of 08/8/2025 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Compare
Annual Income Statements for KalVista Pharmaceuticals

Annual Income Statements for KalVista Pharmaceuticals

This table shows KalVista Pharmaceuticals' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 4/30/2016 4/30/2017 4/30/2018 4/30/2019 4/30/2020 4/30/2021 4/30/2022 4/30/2023 4/30/2024 4/30/2025
Net Income / (Loss) Attributable to Common Shareholders		 -25 -11 -19 -16 -21 -29 -48 -82 -93 -127 -183
Consolidated Net Income / (Loss)		 -25 -11 -19 -16 -21 -29 -46 -82 -93 -127 -183
Net Income / (Loss) Continuing Operations		 -25 -11 -19 -16 -21 -29 -48 -82 -93 -127 -183
Total Pre-Tax Income 		-25 -11 -19 -16 -21 -29 -46 -82 -93 -127 -180
Total Operating Income		 -21 -15 -22 -19 -30 -41 -58 -97 -111 -140 -188
Total Gross Profit		 0.03 2.13 1.50 8.39 16 13 0.00 0.00 0.00 0.00 0.00
Total Revenue		 0.03 2.13 1.50 8.39 16 13 0.00 0.00 0.00 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 21 17 24 27 46 53 58 97 111 140 188
Selling, General & Admin Expense		 4.87 2.65 11 8.86 11 13 17 26 31 54 116
Research & Development Expense		 16 15 13 18 35 40 41 70 80 86 72
Total Other Income / (Expense), net		 -3.81 3.75 3.74 2.90 9.13 11 12 14 18 14 7.94
Interest Expense		 4.37 - - - - - - - - 0.00 5.79
Interest & Investment Income		 0.01 0.05 0.04 0.08 1.40 1.83 0.90 1.09 2.23 3.90 6.44
Other Income / (Expense), net		 0.55 3.70 3.70 2.82 7.73 9.46 9.08 13 16 9.91 7.29
Income Tax Expense		 - - - 0.00 0.12 -0.12 0.00 0.00 0.00 0.00 3.39
Basic Earnings per Share		 ($1.30) ($26.17) ($4.47) ($1.53) ($1.38) ($1.64) ($2.42) ($3.36) ($3.33) ($3.44) ($3.69)
Weighted Average Basic Shares Outstanding		 26.33M 591.30K 4.65M 10.32M 15.08M 17.75M 19.09M 24.47M 27.89M 36.79M 49.65M
Diluted Earnings per Share		 ($1.30) ($26.17) ($4.47) ($1.53) ($1.38) ($1.64) ($2.42) ($3.36) ($3.33) ($3.44) ($3.69)
Weighted Average Diluted Shares Outstanding		 26.33M 591.30K 4.65M 10.32M 15.08M 17.75M 19.09M 24.47M 27.89M 36.79M 49.65M
Weighted Average Basic & Diluted Shares Outstanding		 19.08M 591.30K 4.65M 10.32M 15.08M 17.75M 19.09M 24.57M 34.23M 42.74M 49.95M

Quarterly Income Statements for KalVista Pharmaceuticals

This table shows KalVista Pharmaceuticals' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025
Period end date 10/31/2022 1/31/2023 4/30/2023 7/31/2023 10/31/2023 1/31/2024 4/30/2024 7/31/2024 10/31/2024 1/31/2025 4/30/2025
Net Income / (Loss) Attributable to Common Shareholders		 -22 -21 -26 -25 -28 -29 -45 -40 -42 -49 -52
Consolidated Net Income / (Loss)		 -22 -21 -26 -25 -28 -29 -45 -40 -42 -49 -52
Net Income / (Loss) Continuing Operations		 -22 -21 -26 -25 -28 -29 -45 -40 -42 -49 -52
Total Pre-Tax Income 		-22 -21 -26 -25 -28 -29 -45 -40 -42 -44 -53
Total Operating Income		 -26 -27 -32 -29 -30 -33 -48 -44 -46 -43 -55
Total Operating Expenses		 26 27 32 29 30 33 48 44 46 43 55
Selling, General & Admin Expense		 7.81 6.88 7.78 9.79 11 11 23 18 29 30 39
Research & Development Expense		 18 20 24 19 19 23 25 27 17 13 16
Total Other Income / (Expense), net		 3.63 5.64 5.42 3.78 2.10 4.12 3.81 3.77 3.54 -1.32 1.95
Interest & Investment Income		 0.45 0.73 0.81 0.92 0.78 0.68 1.51 1.69 1.36 1.39 1.99
Other Income / (Expense), net		 3.18 4.91 4.61 2.85 1.32 3.44 2.29 2.08 2.19 0.13 2.90
Basic Earnings per Share		 ($0.90) ($0.75) ($0.74) ($0.74) ($0.80) ($0.84) ($1.06) ($0.87) ($0.91) ($0.92) ($0.99)
Weighted Average Basic Shares Outstanding		 24.60M 28.28M 27.89M 34.41M 34.57M 34.72M 36.79M 46.23M 46.70M 52.64M 49.65M
Diluted Earnings per Share		 ($0.90) ($0.75) ($0.74) ($0.74) ($0.80) ($0.84) ($1.06) ($0.87) ($0.91) ($0.92) ($0.99)
Weighted Average Diluted Shares Outstanding		 24.60M 28.28M 27.89M 34.41M 34.57M 34.72M 36.79M 46.23M 46.70M 52.64M 49.65M
Weighted Average Basic & Diluted Shares Outstanding		 24.62M 34.17M 34.23M 34.40M 34.56M 42.19M 42.74M 43.22M 49.42M 49.72M 49.95M

Annual Cash Flow Statements for KalVista Pharmaceuticals

This table details how cash moves in and out of KalVista Pharmaceuticals' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 4/30/2016 4/30/2017 4/30/2018 4/30/2019 4/30/2020 4/30/2021 4/30/2022 4/30/2023 4/30/2024 4/30/2025
Net Change in Cash & Equivalents		 50 19 9.19 18 -19 -16 35 -20 26 -24 100
Net Cash From Operating Activities		 -21 -13 -24 11 -36 -45 -30 -78 -75 -89 -153
Net Cash From Continuing Operating Activities		 -21 -13 -24 11 -36 -45 -30 -79 -75 -89 -153
Net Income / (Loss) Continuing Operations		 -25 -11 -19 -16 -21 -29 -46 -82 -93 -127 -183
Consolidated Net Income / (Loss)		 -25 -11 -19 -16 -21 -29 -46 -82 -93 -127 -183
Depreciation Expense		 0.13 0.03 0.04 0.18 0.38 0.51 0.54 0.56 0.72 0.82 0.94
Amortization Expense		 0.78 - - 0.00 0.00 0.19 0.69 2.57 0.99 0.09 5.89
Non-Cash Adjustments To Reconcile Net Income		 3.67 -1.68 -0.95 0.73 -2.02 -1.55 14 13 6.21 30 16
Changes in Operating Assets and Liabilities, net		 -0.60 -0.07 -4.21 25 -14 -15 0.89 -12 9.73 6.99 7.78
Net Cash From Investing Activities		 -1.37 -0.01 34 -1.43 -69 17 -148 58 41 -85 91
Net Cash From Continuing Investing Activities		 -1.37 -0.01 34 -1.43 -69 17 -148 58 41 -85 91
Purchase of Property, Plant & Equipment		 -0.66 -0.01 - -1.43 -1.08 -0.22 -0.08 -0.93 -1.20 -0.44 -0.93
Purchase of Investments		 - - - 0.00 -80 -50 -201 -137 -98 -189 -31
Sale and/or Maturity of Investments		 - - - 0.00 12 67 54 196 141 105 123
Net Cash From Financing Activities		 72 33 0.00 8.99 88 12 212 1.58 58 151 160
Net Cash From Continuing Financing Activities		 72 33 0.00 8.99 88 12 212 1.58 58 151 160
Issuance of Common Equity		 68 0.00 - 9.14 88 12 212 1.58 58 151 62
Other Financing Activities, net		 0.16 - 0.00 - - - - - - 0.00 98
Effect of Exchange Rate Changes		 - -0.60 -1.16 - -1.21 0.26 0.51 -1.17 1.24 -1.21 2.64

Quarterly Cash Flow Statements for KalVista Pharmaceuticals

This table details how cash moves in and out of KalVista Pharmaceuticals' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025
Period end date 10/31/2022 1/31/2023 4/30/2023 7/31/2023 10/31/2023 1/31/2024 4/30/2024 7/31/2024 10/31/2024 1/31/2025 4/30/2025
Net Change in Cash & Equivalents		 0.72 46 -29 -6.83 8.26 -35 8.73 0.06 9.73 126 -36
Net Cash From Operating Activities		 -21 -9.29 -23 -27 -20 -28 -15 -40 -40 -33 -40
Net Cash From Continuing Operating Activities		 -21 -9.29 -23 -27 -20 -28 -15 -40 -40 -33 -40
Net Income / (Loss) Continuing Operations		 -22 -21 -26 -25 -28 -29 -45 -40 -42 -49 -52
Consolidated Net Income / (Loss)		 -22 -21 -26 -25 -28 -29 -45 -40 -42 -49 -52
Depreciation Expense		 0.17 0.20 0.19 0.19 0.20 0.21 0.22 0.22 0.23 0.23 0.26
Amortization Expense		 0.29 0.21 0.10 0.06 0.02 0.01 0.00 0.01 0.01 2.93 2.95
Non-Cash Adjustments To Reconcile Net Income		 1.43 3.79 -2.12 2.55 -0.31 0.17 27 2.30 2.18 7.92 3.52
Changes in Operating Assets and Liabilities, net		 -0.23 7.81 5.50 -4.22 7.92 1.07 2.22 -2.31 0.21 4.76 5.13
Net Cash From Investing Activities		 20 -2.52 -6.21 20 29 -6.70 -126 37 49 8.52 -3.33
Net Cash From Continuing Investing Activities		 20 -2.52 -6.21 20 29 -6.70 -126 37 49 8.52 -3.33
Purchase of Property, Plant & Equipment		 -0.19 -0.02 -0.07 -0.01 -0.21 -0.11 -0.12 -0.09 -0.20 -0.13 -0.52
Purchase of Investments		 - -54 -34 -26 -3.77 -18 -142 -0.98 -0.00 -6.56 -23
Sale and/or Maturity of Investments		 20 51 28 45 33 12 15 38 49 15 20
Net Cash From Financing Activities		 0.17 58 -0.03 0.20 0.13 0.28 150 3.00 0.30 152 4.66
Net Cash From Continuing Financing Activities		 0.17 58 -0.03 0.20 0.13 0.28 150 3.00 0.30 152 4.66
Issuance of Common Equity		 0.17 58 -0.03 0.20 0.13 0.28 150 3.00 0.30 57 1.85
Other Financing Activities, net		 - - - - - - - - - - 2.81
Effect of Exchange Rate Changes		 1.05 0.46 0.07 0.08 -0.60 -0.62 -0.07 0.12 0.41 -1.25 3.36

Annual Balance Sheets for KalVista Pharmaceuticals

This table presents KalVista Pharmaceuticals' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 4/30/2016 4/30/2017 4/30/2018 4/30/2019 4/30/2020 4/30/2021 4/30/2022 4/30/2023 4/30/2024 4/30/2025
Total Assets		 57 25 34 61 118 93 272 204 183 235 251
Total Current Assets		 55 25 34 59 116 89 264 194 172 226 242
Cash & Equivalents		 54 22 31 51 32 16 51 31 56 32 132
Short-Term Investments		 - - - - 69 52 198 135 93 179 89
Prepaid Expenses		 1.22 0.67 0.70 1.49 3.42 4.46 4.92 13 6.38 6.85 20
Other Current Assets		 - 0.36 0.30 6.83 11 17 10 14 17 8.44 1.38
Plant, Property, & Equipment, net		 0.81 0.07 0.10 1.84 2.41 2.04 1.79 2.18 2.95 2.23 1.99
Total Noncurrent Assets		 1.04 0.00 0.05 0.17 0.17 1.79 5.96 8.06 7.93 7.49 7.09
Other Noncurrent Operating Assets		 0.99 - 0.05 0.17 0.17 1.79 5.96 8.06 7.93 7.49 7.09
Total Liabilities & Shareholders' Equity		 57 25 34 61 118 93 272 204 183 235 251
Total Liabilities		 7.48 3.25 3.02 34 21 8.78 15 19 22 29 155
Total Current Liabilities		 4.27 3.25 3.02 23 18 7.72 9.77 12 15 23 45
Accounts Payable		 1.46 1.14 1.15 1.43 2.86 1.68 1.98 3.64 4.82 9.11 4.88
Accrued Expenses		 1.33 2.11 1.87 3.09 5.65 5.46 6.93 6.96 9.13 12 27
Current Deferred Revenue		 0.03 - - 18 9.55 - - - - 0.00 11
Other Current Liabilities		 - - - - 0.00 0.59 0.86 0.98 1.09 1.30 1.98
Total Noncurrent Liabilities		 3.21 0.00 0.00 11 3.34 1.06 5.05 7.21 7.15 6.02 110
Capital Lease Obligations		 - - - 0.06 - - - - - 6.02 4.33
Other Noncurrent Operating Liabilities		 - - - - 0.00 1.06 5.05 7.21 7.15 0.00 106
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 49 -37 31 27 97 84 257 185 161 207 95
Total Preferred & Common Equity		 49 -37 31 27 97 84 257 185 161 207 95
Total Common Equity		 49 -37 31 27 97 84 257 185 161 207 95
Common Stock		 122 0.22 90 100 191 207 426 439 507 680 754
Retained Earnings		 -73 -37 -56 -72 -92 -122 -168 -250 -343 -470 -653
Accumulated Other Comprehensive Income / (Loss)		 - -0.08 -2.64 -1.11 -1.93 -1.88 -1.43 -3.86 -3.06 -3.49 -5.21

Quarterly Balance Sheets for KalVista Pharmaceuticals

This table presents KalVista Pharmaceuticals' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025
Period end date 7/31/2022 10/31/2022 1/31/2023 7/31/2023 10/31/2023 1/31/2024 7/31/2024 10/31/2024 1/31/2025
Total Assets		 182 163 203 160 139 114 200 161 276
Total Current Assets		 170 151 192 150 129 104 192 152 267
Cash & Equivalents		 38 39 85 49 58 23 32 42 167
Short-Term Investments		 104 84 87 74 46 53 142 94 86
Prepaid Expenses		 11 8.91 8.56 7.53 5.46 5.51 7.45 5.41 6.67
Other Current Assets		 17 20 12 19 20 23 9.91 11 7.49
Plant, Property, & Equipment, net		 3.03 3.06 3.04 2.81 2.50 2.42 2.10 2.04 1.81
Total Noncurrent Assets		 8.88 8.56 8.30 7.68 7.64 7.44 6.46 6.53 6.83
Other Noncurrent Operating Assets		 8.88 8.56 8.30 7.68 7.64 7.44 6.46 6.53 6.83
Total Liabilities & Shareholders' Equity		 182 163 203 160 139 114 200 161 276
Total Liabilities		 18 19 19 21 24 25 27 27 131
Total Current Liabilities		 9.73 11 12 14 18 19 22 22 26
Accounts Payable		 2.91 3.38 1.70 5.06 4.90 3.10 11 5.20 5.86
Accrued Expenses		 5.83 6.91 8.85 7.95 12 15 10 15 18
Other Current Liabilities		 1.00 1.03 1.06 1.12 1.15 1.19 1.26 1.54 1.44
Total Noncurrent Liabilities		 8.01 7.71 7.42 6.87 6.55 6.26 4.99 4.68 105
Capital Lease Obligations		 - - - - - - - 4.68 4.34
Other Noncurrent Operating Liabilities		 8.01 7.71 7.42 6.87 6.55 6.26 4.99 - 101
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 165 144 184 139 114 89 173 134 145
Total Preferred & Common Equity		 165 144 184 139 114 89 173 134 145
Total Common Equity		 165 144 184 139 114 89 173 134 145
Common Stock		 442 445 505 511 514 517 686 689 748
Retained Earnings		 -273 -295 -317 -368 -396 -425 -510 -552 -601
Accumulated Other Comprehensive Income / (Loss)		 -4.15 -5.33 -3.54 -2.89 -3.47 -3.29 -2.87 -2.70 -2.21

Annual Metrics And Ratios for KalVista Pharmaceuticals

This table displays calculated financial ratios and metrics derived from KalVista Pharmaceuticals' official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 4/30/2016 4/30/2017 4/30/2018 4/30/2019 4/30/2020 4/30/2021 4/30/2022 4/30/2023 4/30/2024 4/30/2025
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 7,255.17% -29.49% 458.11% 92.13% -21.31% -100.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 -65.30% 41.49% -62.39% 15.55% -38.23% -39.86% -56.82% -68.63% -16.35% -38.74% -34.13%
EBIT Growth		 -66.84% 43.93% -62.28% 14.76% -39.04% -40.66% -57.20% -70.82% -14.04% -37.21% -38.43%
NOPAT Growth		 -80.15% 27.83% -47.15% 16.27% -59.42% -35.93% -42.90% -66.80% -14.76% -26.67% -33.86%
Net Income Growth		 -85.99% 53.97% -62.67% 15.04% -31.71% -39.87% -58.83% -78.05% -12.83% -36.31% -44.85%
EPS Growth		 94.04% 53.97% 82.92% 65.77% 9.80% -18.84% -47.56% -38.84% 0.89% -3.30% -7.27%
Operating Cash Flow Growth		 -85.40% 36.94% -80.31% 144.51% -444.43% -23.24% 32.68% -158.97% 3.68% -18.56% -71.36%
Free Cash Flow Firm Growth		 -147.54% 37.78% -59.43% 166.37% -473.15% -20.24% 32.41% -138.79% 10.08% -17.73% 90.43%
Invested Capital Growth		 109.46% -283.56% 240.67% -6,339.52% 82.69% 493.76% -48.47% 128.59% -38.33% -132.78% -5,605.28%
Revenue Q/Q Growth		 0.00% 7,255.17% -57.42% 130.73% -10.60% 7.61% -100.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 -2.11% 46.26% -85.08% 18.43% -58.23% 5.53% -24.93% -10.08% -3.42% -17.29% -1.74%
EBIT Q/Q Growth		 -6.23% 46.50% -86.50% 18.10% -57.46% 5.22% -25.40% -9.76% -2.96% -17.08% -3.41%
NOPAT Q/Q Growth		 -9.09% 29.28% -35.01% 10.13% -38.50% 5.37% -18.60% -9.98% -4.64% -13.52% -3.62%
Net Income Q/Q Growth		 -3.95% 48.02% -96.44% 18.43% -60.78% 6.25% -22.11% -12.51% -2.42% -16.94% -4.31%
EPS Q/Q Growth		 -42.86% 48.02% -249.22% 15.00% -84.00% 5.20% -14.15% -10.16% 6.72% -10.26% 1.86%
Operating Cash Flow Q/Q Growth		 -3.63% 30.86% -16.99% -23.89% -14.32% -4.93% 4.96% -25.23% 5.23% 7.78% -19.79%
Free Cash Flow Firm Q/Q Growth		 0.00% 35.23% -25.90% -34.72% -6.57% -2.96% -1.35% -17.88% 4.62% 4.61% 17.10%
Invested Capital Q/Q Growth		 119.70% 0.00% -72.09% 20.99% 41.86% 58.74% 0.12% 43.69% -8.67% -129.38% -16.54%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 -67,493.10% -536.94% -1,236.64% -187.12% -134.63% -239.28% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 -72,537.93% -711.72% -1,485.31% -222.84% -184.91% -319.41% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 -70,641.38% -538.49% -1,239.30% -189.27% -136.97% -244.84% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 -85,675.86% -536.15% -1,236.90% -188.29% -129.08% -229.44% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.60% 99.58% 100.00% 100.00% 100.00% 100.00% 101.88%
Interest Burden Percent		 121.28% 99.56% 99.81% 99.48% 93.68% 94.11% 94.68% 98.69% 97.65% 97.02% 99.64%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% -28,692.29% 0.00% 0.00% -474.27% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% -28,681.04% 0.00% 0.00% -473.39% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 28,621.86% 0.00% 0.00% 442.01% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -968.84% -32.30% -70.44% -53.96% -33.58% -32.26% -27.13% -37.23% -53.69% -68.90% -121.50%
Cash Return on Invested Capital (CROIC)		 -11,242.60% 0.00% -4,318.91% 0.00% 0.00% -302.31% -269.71% -576.37% -460.81% 0.00% 0.00%
Operating Return on Assets (OROA)		 -64.59% -28.17% -63.09% -33.19% -24.61% -29.50% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 -78.34% -28.05% -62.97% -33.02% -23.19% -27.64% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -968.84% -5.56% 7.71% -53.96% -33.58% -32.26% -27.13% -37.23% -53.69% -68.90% -121.50%
Return on Equity Simple (ROE_SIMPLE)		 -50.39% 30.81% -59.38% -57.99% -21.52% -34.76% -17.98% -44.49% -57.70% -61.30% -192.31%
Net Operating Profit after Tax (NOPAT)		 -15 -11 -16 -13 -21 -28 -41 -68 -78 -98 -132
NOPAT Margin		 -50,776.55% -498.20% -1,039.71% -155.99% -129.44% -223.59% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -310.17% -2.28% -11.25% -6.64% 0.08% -0.88% -3.60% -7.09% -9.69% -15.75% -24.65%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - - - - -131.96%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 16,779.31% 124.38% 743.15% 105.58% 67.75% 102.67% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 55,858.62% 687.34% 842.15% 217.26% 217.16% 316.74% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 72,637.93% 811.72% 1,585.31% 322.84% 284.91% 419.41% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -20 -11 -19 -16 -22 -31 -49 -83 -95 -131 -181
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -20 -11 -19 -16 -22 -30 -48 -80 -93 -130 -174
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 1.93 0.00 2.32 3.81 4.10 2.32 2.36 1.69 1.81 2.32 7.18
Price to Tangible Book Value (P/TBV)		 1.93 0.00 2.32 3.81 4.10 2.32 2.36 1.69 1.81 2.32 7.18
Price to Revenue (P/Rev)		 3,285.77 9.04 48.36 12.37 24.60 15.34 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 316.26 0.00 110.84 0.00 0.00 7.92 43.33 7.74 12.20 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 1,592.19 26.31 27.78 6.32 18.35 10.01 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 5.03 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 4.91 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.09 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.05
Long-Term Debt to Equity		 0.06 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.05
Financial Leverage		 -1.27 -1.00 -1.00 -1.40 -1.22 -0.93 -0.93 -0.94 -0.91 -0.98 -1.39
Leverage Ratio		 12.37 1.15 1.12 1.63 1.45 1.17 1.07 1.08 1.12 1.14 1.61
Compound Leverage Factor		 15.00 1.15 1.12 1.63 1.36 1.10 1.01 1.06 1.09 1.10 1.60
Debt to Total Capital		 8.55% 0.00% 0.00% 1.01% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 4.34%
Short-Term Debt to Total Capital		 2.70% 0.00% 0.00% 0.80% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 5.85% 0.00% 0.00% 0.21% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 4.34%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 272.65% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 91.45% -172.65% 100.00% 98.99% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 95.66%
Debt to EBITDA		 -0.24 0.00 0.00 -0.02 0.00 0.00 0.00 0.00 0.00 0.00 -0.02
Net Debt to EBITDA		 2.51 0.00 0.00 3.23 0.00 0.00 0.00 0.00 0.00 0.00 1.24
Long-Term Debt to EBITDA		 -0.16 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.02
Debt to NOPAT		 -0.31 0.00 0.00 -0.02 0.00 0.00 0.00 0.00 0.00 0.00 -0.03
Net Debt to NOPAT		 3.34 0.00 0.00 3.88 0.00 0.00 0.00 0.00 0.00 0.00 1.64
Long-Term Debt to NOPAT		 -0.21 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.03
Altman Z-Score		 5.73 1.05 11.53 0.18 10.54 11.55 24.24 7.98 4.58 6.38 -2.44
Noncontrolling Interest Sharing Ratio		 0.00% 82.77% 110.95% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 12.86 7.59 11.33 2.56 6.40 11.49 27.04 16.73 11.46 9.90 5.35
Quick Ratio		 12.58 6.70 10.26 2.20 5.58 8.77 25.47 14.36 9.94 9.23 4.88
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -16 -10 -16 11 -40 -48 -33 -78 -70 -83 -8.50
Operating Cash Flow to CapEx		 -3,165.86% -119,600.00% 0.00% 739.87% -3,364.01% -20,370.91% -36,793.90% -8,392.48% -6,292.73% -20,142.44% -16,459.31%
Free Cash Flow to Firm to Interest Expense		 -3.76 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -1.47
Operating Cash Flow to Interest Expense		 -4.78 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -26.43
Operating Cash Flow Less CapEx to Interest Expense		 -4.93 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -26.59
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.05 0.05 0.18 0.18 0.12 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.06 4.85 17.59 8.68 7.59 5.70 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 0.15 -0.27 0.38 -24 -4.07 16 8.26 19 12 -3.82 -121
Invested Capital Turnover		 -0.04 -34.97 27.60 -0.73 -1.17 2.12 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 1.69 -0.41 0.65 -24 19 20 -7.77 11 -7.24 -15 -123
Enterprise Value (EV)		 46 56 42 53 296 127 358 146 142 268 468
Market Capitalization		 95 19 73 104 397 195 607 312 291 479 685
Book Value per Share		 $1.87 ($1.41) $3.23 $2.52 $5.61 $4.69 $10.58 $7.54 $4.71 $4.90 $1.92
Tangible Book Value per Share		 $1.87 ($1.41) $3.23 $2.52 $5.61 $4.69 $10.58 $7.54 $4.71 $4.90 $1.92
Total Capital		 54 21 31 28 97 84 257 185 161 207 100
Total Debt		 4.61 0.00 0.00 0.28 0.00 0.00 0.00 0.00 0.00 0.00 4.33
Total Long-Term Debt		 3.15 0.00 0.00 0.06 0.00 0.00 0.00 0.00 0.00 0.00 4.33
Net Debt		 -49 -22 -31 -51 -101 -68 -249 -166 -149 -210 -216
Capital Expenditures (CapEx)		 0.66 0.01 -0.07 1.43 1.08 0.22 0.08 0.93 1.20 0.44 0.93
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -1.59 -0.34 0.23 -15 -3.32 13 5.56 16 7.92 -7.52 -24
Debt-free Net Working Capital (DFNWC)		 52 21 31 36 97 81 254 182 157 203 197
Net Working Capital (NWC)		 51 21 31 36 97 81 254 182 157 203 197
Net Nonoperating Expense (NNE)		 10 0.81 2.97 2.71 -0.06 0.74 5.70 15 15 28 52
Net Nonoperating Obligations (NNO)		 -49 -22 -31 -51 -101 -68 -249 -166 -149 -210 -216
Total Depreciation and Amortization (D&A)		 0.91 0.03 0.04 0.18 0.38 0.71 1.22 3.13 1.71 0.91 6.83
Debt-free, Cash-free Net Working Capital to Revenue		 -5,496.55% -16.03% 15.29% -174.77% -20.57% 104.51% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 179,755.17% 1,004.31% 2,073.14% 433.46% 604.54% 638.11% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 174,737.93% 1,004.31% 2,073.14% 430.83% 604.54% 638.11% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($18.20) ($26.17) ($4.47) ($1.53) ($1.38) ($1.64) ($2.42) ($3.36) ($3.33) ($3.44) ($3.69)
Adjusted Weighted Average Basic Shares Outstanding		 1.88M 591.30K 9.71M 10.80M 17.39M 17.85M 24.44M 24.47M 27.89M 36.79M 49.65M
Adjusted Diluted Earnings per Share		 ($18.20) ($26.17) ($4.47) ($1.53) ($1.38) ($1.64) ($2.42) ($3.36) ($3.33) ($3.44) ($3.69)
Adjusted Weighted Average Diluted Shares Outstanding		 1.88M 591.30K 9.71M 10.80M 17.39M 17.85M 24.44M 24.47M 27.89M 36.79M 49.65M
Adjusted Basic & Diluted Earnings per Share		 ($18.20) ($26.17) ($4.47) ($1.53) ($1.38) ($1.64) ($2.42) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 1.36M 591.30K 4.65M 10.32M 15.08M 17.75M 19.09M 24.57M 34.23M 42.74M 49.95M
Normalized Net Operating Profit after Tax (NOPAT)		 -15 -11 -16 -13 -21 -28 -41 -68 -78 -98 -132
Normalized NOPAT Margin		 -50,776.55% -498.20% -1,039.71% -155.99% -129.44% -223.59% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 -85,675.86% -536.15% -1,236.90% -188.29% -128.31% -230.42% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -4.69 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -31.24
NOPAT to Interest Expense		 -3.37 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -22.75
EBIT Less CapEx to Interest Expense		 -4.84 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -31.40
NOPAT Less CapEx to Interest Expense		 -3.52 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -22.91
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for KalVista Pharmaceuticals

This table displays calculated financial ratios and metrics derived from KalVista Pharmaceuticals' official financial filings.

Metric Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025
Period end date 10/31/2022 1/31/2023 4/30/2023 7/31/2023 10/31/2023 1/31/2024 4/30/2024 7/31/2024 10/31/2024 1/31/2025 4/30/2025
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 -16.22% 1.35% -13.00% -14.30% -26.80% -36.42% -71.24% -61.27% -53.83% -34.44% -6.48%
EBIT Growth		 -13.87% 3.04% -11.21% -12.70% -25.19% -34.84% -70.25% -60.58% -53.47% -44.10% -12.92%
NOPAT Growth		 -9.66% -0.98% -18.34% -10.55% -14.92% -23.03% -52.72% -51.98% -54.01% -29.53% -13.57%
Net Income Growth		 -13.27% 5.18% -9.09% -9.87% -24.23% -36.26% -69.74% -59.75% -52.87% -67.11% -16.97%
EPS Growth		 -12.50% 18.48% 24.49% 21.28% 11.11% -12.00% -43.24% -17.57% -13.75% -9.52% 6.60%
Operating Cash Flow Growth		 -5.37% 33.96% 15.50% -17.54% 3.73% -196.81% 33.27% -50.47% -99.96% -18.53% -167.22%
Free Cash Flow Firm Growth		 8.88% 21.64% 49.08% 48.57% 52.02% -26.94% -23.26% 3.92% -124.37% 469.68% 445.69%
Invested Capital Growth		 21.98% -2.97% -38.33% -28.53% -47.66% 1.89% -132.78% -109.16% -74.36% -898.18% -5,605.28%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 2.15% 2.80% -24.07% 3.14% -8.55% -4.58% -55.73% 8.78% -3.55% 8.60% -23.34%
EBIT Q/Q Growth		 2.48% 2.96% -23.05% 3.22% -8.33% -4.52% -55.36% 8.72% -3.54% 1.86% -21.75%
NOPAT Q/Q Growth		 1.65% -4.10% -17.75% 8.30% -2.24% -11.45% -46.16% 8.75% -3.61% 6.27% -28.15%
Net Income Q/Q Growth		 3.41% 4.29% -23.48% 3.76% -9.22% -4.98% -53.81% 9.42% -4.51% -14.77% -7.66%
EPS Q/Q Growth		 4.26% 16.67% 1.33% 0.00% -8.11% -5.00% -26.19% 17.92% -4.60% -1.10% -7.61%
Operating Cash Flow Q/Q Growth		 9.45% 54.89% -143.69% -18.09% 25.83% -39.07% 45.21% -166.27% 1.44% 17.56% -23.51%
Free Cash Flow Firm Q/Q Growth		 18.88% 16.04% 18.96% 6.83% 24.31% -122.11% 21.31% 27.37% -76.76% 465.97% -2.43%
Invested Capital Q/Q Growth		 -4.25% -40.78% -8.67% 38.01% -29.88% 15.28% -129.38% 61.43% 296.27% -3,688.34% -16.54%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 109.60% 98.39%
Interest Burden Percent		 98.02% 96.68% 97.02% 96.48% 97.27% 97.70% 96.72% 95.98% 96.89% 103.38% 101.82%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -49.49% -46.24% -53.69% -62.64% -77.89% -79.33% -68.90% -90.84% -125.90% -150.50% -121.50%
Cash Return on Invested Capital (CROIC)		 -397.29% -569.64% -460.81% -379.18% -438.79% -674.43% 0.00% 0.00% -1,577.97% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -49.49% -46.24% -53.69% -62.64% -77.89% -79.33% -68.90% -90.84% -125.90% -150.50% -121.50%
Return on Equity Simple (ROE_SIMPLE)		 -63.89% -49.18% 0.00% -68.31% -87.88% -122.26% 0.00% -82.04% -116.71% -121.18% 0.00%
Net Operating Profit after Tax (NOPAT)		 -18 -19 -22 -20 -21 -23 -34 -31 -32 -30 -39
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -2.49% -1.33% -2.60% -3.73% -6.06% -4.71% -5.97% -6.38% -8.71% -11.37% -6.52%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - -26.20% - - - -20.11% -38.63%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -23 -22 -27 -26 -28 -30 -46 -42 -44 -43 -52
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -22 -22 -27 -26 -28 -30 -46 -42 -43 -40 -49
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.87 1.06 1.81 2.48 2.55 6.15 2.32 3.60 3.31 3.03 7.18
Price to Tangible Book Value (P/TBV)		 0.87 1.06 1.81 2.48 2.55 6.15 2.32 3.60 3.31 3.03 7.18
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.11 1.90 12.20 13.84 16.76 36.12 0.00 0.00 108.17 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.03 0.03 0.05
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.03 0.03 0.05
Financial Leverage		 -0.89 -0.93 -0.91 -0.87 -0.87 -0.91 -0.98 -0.95 -0.94 -1.39 -1.39
Leverage Ratio		 1.10 1.09 1.12 1.13 1.17 1.16 1.14 1.16 1.21 1.67 1.61
Compound Leverage Factor		 1.07 1.06 1.09 1.09 1.14 1.14 1.10 1.11 1.17 1.73 1.64
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 3.37% 2.90% 4.34%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 3.37% 2.90% 4.34%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 96.63% 97.10% 95.66%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.03 -0.03 -0.02
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.82 1.46 1.24
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.03 -0.03 -0.02
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.04 -0.03 -0.03
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.09 1.96 1.64
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.04 -0.03 -0.03
Altman Z-Score		 1.96 4.71 5.81 7.14 3.50 7.69 7.56 10.36 5.19 -0.49 -0.75
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 13.36 16.55 11.46 10.60 7.25 5.44 9.90 8.55 6.87 10.44 5.35
Quick Ratio		 10.80 14.79 9.94 8.72 5.81 3.95 9.23 7.78 6.13 9.89 4.88
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -22 -18 -15 -14 -11 -23 -18 -13 -24 87 85
Operating Cash Flow to CapEx		 -10,726.04% -61,926.67% -32,805.80% -445,500.00% -9,670.73% -25,064.55% -12,381.15% -47,317.65% -19,624.75% -25,733.07% -7,837.67%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 30.50 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -11.50 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -11.54 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 22 13 12 16 11 13 -3.82 -1.47 2.89 -104 -121
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 3.88 -0.39 -7.24 -6.42 -10 0.24 -15 -18 -8.38 -117 -123
Enterprise Value (EV)		 2.46 24 142 223 189 469 268 447 313 191 468
Market Capitalization		 125 196 291 346 292 545 479 621 444 440 685
Book Value per Share		 $5.85 $7.49 $4.71 $4.07 $3.33 $2.56 $4.90 $4.04 $3.10 $2.94 $1.92
Tangible Book Value per Share		 $5.85 $7.49 $4.71 $4.07 $3.33 $2.56 $4.90 $4.04 $3.10 $2.94 $1.92
Total Capital		 144 184 161 139 114 89 207 173 139 149 100
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 4.68 4.34 4.33
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 4.68 4.34 4.33
Net Debt		 -122 -172 -149 -123 -103 -76 -210 -174 -131 -249 -216
Capital Expenditures (CapEx)		 0.19 0.02 0.07 0.01 0.21 0.11 0.12 0.09 0.20 0.13 0.52
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 18 8.84 7.92 12 7.68 9.39 -7.52 -5.05 -5.67 -11 -24
Debt-free Net Working Capital (DFNWC)		 140 181 157 136 111 85 203 169 130 242 197
Net Working Capital (NWC)		 140 181 157 136 111 85 203 169 130 242 197
Net Nonoperating Expense (NNE)		 4.14 2.44 4.10 4.95 6.83 5.82 11 9.49 10 18 14
Net Nonoperating Obligations (NNO)		 -122 -172 -149 -123 -103 -76 -210 -174 -131 -249 -216
Total Depreciation and Amortization (D&A)		 0.46 0.41 0.29 0.26 0.22 0.21 0.22 0.23 0.23 3.15 3.21
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.90) ($0.75) ($0.74) ($0.74) ($0.80) ($0.84) ($1.06) ($0.87) ($0.91) ($0.92) ($0.99)
Adjusted Weighted Average Basic Shares Outstanding		 24.60M 28.28M 27.89M 34.41M 34.57M 34.72M 36.79M 46.23M 46.70M 52.64M 49.65M
Adjusted Diluted Earnings per Share		 ($0.90) ($0.75) ($0.74) ($0.74) ($0.80) ($0.84) ($1.06) ($0.87) ($0.91) ($0.92) ($0.99)
Adjusted Weighted Average Diluted Shares Outstanding		 24.60M 28.28M 27.89M 34.41M 34.57M 34.72M 36.79M 46.23M 46.70M 52.64M 49.65M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 24.62M 34.17M 34.23M 34.40M 34.56M 42.19M 42.74M 43.22M 49.42M 49.72M 49.95M
Normalized Net Operating Profit after Tax (NOPAT)		 -18 -19 -22 -20 -21 -23 -34 -31 -32 -30 -39
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -15.06 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -10.58 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -15.11 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -10.62 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Key Financial Trends

KalVista Pharmaceuticals has experienced consistent net losses over the past several quarters and years, reflecting ongoing high operating expenses relative to zero revenue. The company continues to invest heavily in research and development as it aims to develop its pharmaceutical pipeline.

  • No operating revenue has been reported across all quarters in the last two years, consistent with early-stage biopharma development status focusing on R&D rather than sales.
  • Research & Development expenses have remained significant and show a general increase from about $18M in early 2023 to over $15M by Q4 2025, indicating sustained investment in product development.
  • Selling, General & Administrative expenses have increased as well, from roughly $7.7M in Q4 2023 to nearly $39.1M in Q4 2025, suggesting expansion efforts in infrastructure and support.
  • Cash and equivalents have grown substantially from around $37.9M in Q1 2023 to $167.3M by Q3 2025, supported by equity financing activities, indicating strong liquidity position to fund operations.
  • Frequent issuances of common equity have raised cash inflows, with large financing proceeds, such as $150M in Q4 2024 and $151.8M in Q3 2025, bolstering capital resources for ongoing R&D.
  • Total operating expenses have steadily increased from approximately $26M in Q1 2023 to over $55M in Q4 2025, raising the cash burn risk but aligning with growth and pipeline progression.
  • No revenue generation so far highlights dependency on external financing and successful clinical milestones for future profitability.
  • Net cash used in operating activities has ranged roughly from -$9M to -$40M quarterly, indicating ongoing negative cash flows due to heavy operating costs.
  • Net losses have widened over time from about -$23M per quarter in early 2023 to over -$52M in Q4 2025, resulting in cumulative retained earnings deficits exceeding -$600M.
  • Total liabilities have increased along with expansion, reaching approximately $131M in Q3 2025, which may impose obligations and leverage risk though mostly driven by accrued expenses and other liabilities.

In summary, KalVista Pharmaceuticals remains in a development stage, investing heavily in research and general operations without any current revenue. The company has maintained strong capital raising activities to bolster liquidity and fund its operating losses. However, the widening annual net losses and increasing expenses emphasize the need for clinical and commercial milestones to justify ongoing investment risk.

08/09/25 08:02 AMAI Generated. May Contain Errors.

Frequently Asked Questions About KalVista Pharmaceuticals' Financials

When does KalVista Pharmaceuticals' financial year end?

According to the most recent income statement we have on file, KalVista Pharmaceuticals' fiscal year ends in April. Their fiscal year 2025 ended on April 30, 2025.

How has KalVista Pharmaceuticals' net income changed over the last 10 years?

KalVista Pharmaceuticals' net income appears to be on an upward trend, with a most recent value of -$183.44 million in 2025, rising from -$24.85 million in 2015. The previous period was -$126.64 million in 2024. Check out KalVista Pharmaceuticals' forecast to explore projected trends and price targets.

What is KalVista Pharmaceuticals' operating income?
KalVista Pharmaceuticals' total operating income in 2025 was -$188.00 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $188.00 million
How has KalVista Pharmaceuticals' revenue changed over the last 10 years?

Over the last 10 years, KalVista Pharmaceuticals' total revenue changed from $29 thousand in 2015 to $0.00 in 2025, a change of -100.0%.

How much debt does KalVista Pharmaceuticals have?

KalVista Pharmaceuticals' total liabilities were at $155.38 million at the end of 2025, a 439.1% increase from 2024, and a 1,977.0% increase since 2015.

How much cash does KalVista Pharmaceuticals have?

In the past 10 years, KalVista Pharmaceuticals' cash and equivalents has ranged from $15.79 million in 2020 to $131.62 million in 2025, and is currently $131.62 million as of their latest financial filing in 2025.

How has KalVista Pharmaceuticals' book value per share changed over the last 10 years?

Over the last 10 years, KalVista Pharmaceuticals' book value per share changed from 1.87 in 2015 to 1.92 in 2025, a change of 2.4%.


Related Companies

This page (NASDAQ:KALV) was last updated on 8/9/2025 by MarketBeat.com Staff
From Our Partners
Trump’s national nightmare is here
Porter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...
Porter & Company | Sponsored
Elon’s Secret Social Security Bombshell
To All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...
Banyan Hill Publishing | Sponsored
Man Who Called Nvidia at $1.10 Says Buy This Now...
In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...
The Oxford Club | Sponsored
Crypto Income (almost instantly)
How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...
Awesomely, LLC | Sponsored
One stock to replace Nvidia
I'm a Futurist: Here are 3 stocks better than Nvidia Nvidia's own customers could soon become fierce compet...
InvestorPlace | Sponsored
INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off
Right now, we’re witnessing a monumental shift in the world.
Traders Agency | Sponsored
Crypto bros: Meet your replacement
Larry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...
Brownstone Research | Sponsored
Utah’s New Oil Find
The Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...
Stansberry Research | Sponsored